<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026008</url>
  </required_header>
  <id_info>
    <org_study_id>SR1375-101</org_study_id>
    <nct_id>NCT05026008</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of SR1375 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIMR (Australia) Biotech Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai SIMR Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of&#xD;
      SR1375 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 1,randomized, double-blind, placebo-controlled, 2-part study to&#xD;
      evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and&#xD;
      multiple ascending doses of SR1375 in healthy volunteers. The study is divided into two&#xD;
      parts, Part A (single ascending dose [SAD]) and Part B (multiple ascending dose [MAD]). In&#xD;
      Part A, the scheduled dose cohorts include 1, 3, 10, 30, 100, and 200 mg; in Part B, the&#xD;
      planned dose range will be 5, 15, and 50 mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE (Adverse Event)</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Incidence, type and severity and causality of AEs (including withdrawals due to safety or tolerability reasons)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PK : Tmax</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Plasma PK : Time to Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK : Ctrough</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Plasma PK : Trough concentrations (Ctrough) (Part B only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK : AUC0-t</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Plasma PK : Area under the concentration-time curve from 0 to time of last quantifiable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK : AUC0-∞</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Plasma PK : Area under the concentration-time curve from t=0 to infinity (AUC0-∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PK: Ae</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Urine PK: Cumulative amount of unchanged drug excreted in urine (Ae)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PK: CLr</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Urine PK: Renal clearance (CLr)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SR1375 Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of SR1375 capsules orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of placebo capsules orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR1375</intervention_name>
    <description>The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water</description>
    <arm_group_label>SR1375 Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy volunteers will be included in the study if they satisfy all the following&#xD;
        criteria:&#xD;
&#xD;
          1. Must have given written informed consent before any study-related activities are&#xD;
             carried out and must be able to understand the full nature and purpose of the trial,&#xD;
             including possible risks and adverse effects.&#xD;
&#xD;
          2. Adult males, 18 to 55 years of age (inclusive) at screening.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2, with a body weight ≥ 50 kg at screening.&#xD;
&#xD;
          4. Use of tobacco or nicotine-containing products:&#xD;
&#xD;
          5. Medically healthy without clinically significant abnormalities at the screening visit,&#xD;
             at check-in on Day -1 and pre-dose on Day 1.&#xD;
&#xD;
          6. Conventional 12-lead ECG recording in triplicate (the mean of triplicate measurements&#xD;
             will be used to determine eligibility at the screening visit, on Day -1 and pre-dose&#xD;
             on Day 1) consistent with normal cardiac conduction and function.&#xD;
&#xD;
          7. Have suitable venous access for blood sampling.&#xD;
&#xD;
          8. Be willing and able to comply with all study assessments and adhere to the protocol&#xD;
             schedule and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Volunteers will be excluded from the study if there is evidence of any of the following:&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological&#xD;
             disease, including any acute illness or major surgery within the past three months&#xD;
             determined by the Investigator to be clinically relevant.&#xD;
&#xD;
          2. Any history of malignant disease in the last 10 years (excluding completely treated&#xD;
             cutaneous squamous cell or basal cell carcinoma).&#xD;
&#xD;
          3. Liver function test results (i.e., aspartate aminotransferase [AST], alanine&#xD;
             aminotransferase [ALT], and gamma glutamyl transferase [GGT]) and bilirubin (total,&#xD;
             conjugated and unconjugated) elevated more than 1.5-fold above the upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          4. Positive test results for active human immunodeficiency virus (HIV-1 and HIV-2),&#xD;
             hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the&#xD;
             screening visit.&#xD;
&#xD;
          5. Presence or having sequelae of gastrointestinal, liver (including Gilbert's syndrome),&#xD;
             kidney, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of drugs. Exception: cholecystectomy is allowed.&#xD;
&#xD;
          6. History of substance abuse or alcohol abuse defined as &gt;21 units of alcohol per week&#xD;
             for males and &gt;14 units of alcohol per week for females. One unit is equivalent to 8 g&#xD;
             of alcohol: a half-pint (~285 mL) of beer, 1 glass (125 mL) of wine or 1 measure (25&#xD;
             mL) of spirits.&#xD;
&#xD;
          7. Is an employee of an Investigator or Sponsor or an immediate relative of an&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Redfern</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pan Wang</last_name>
    <phone>+86 13795373965</phone>
    <email>pwang@simrbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tony Zhou</last_name>
    <phone>+86 13918653499</phone>
    <email>gczhou@simrbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Redfern</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

